Modulators of cystic fibrosis transmembrane conductance regulator

US10738030B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Brian Bear · Oceanside, US
• Jeremy J. Clemens · San Diego, US
• Thomas Cleveland · San Diego, US
• Timothy Richard Coon · Carlsbad, US
• Peter Diederik Jan Grootenhuis · San Diego, US
• Bryan A. Frieman · Village of La Jolla, US
• Sara S. Hadida Ruah · Village of La Jolla, US
• Haripada Khatuya · San Diego, US
• Paul Krenitsky · San Diego, US
• Mark Miller · San Diego, US
• Alina Silina · San Diego, US
• Johnny Uy · San Diego, US
• Jinglan Zhou · San Diego, US

Key dates

• Filing date: Mar 31, 2017
• Grant date: Aug 11, 2020
• Expiry date: Mar 31, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R1, R2, W, X, Z, n, p, and Rings A and B are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present disclosure also features pharmaceutical compositions, method of treating, and kits thereof.